IRON241220P85000
- 0.00
- 0.000.00%
Disc Medicine Newsroom
Express News | Disc Medicine Inc: - To Issue and Sell up to $200 Million in Common Stock
Express News | Disc Medicine Inc: Entered Into a Controlled Equity Offering SM Sales Agreement With Cantor Fitzgerald & Co.
Disc Medicine Announces New Equity Sales Agreement
Disc Medicine Reports Q3 2024 Results and Strategic Progress
Disc Medicine Is Maintained at Buy by HC Wainwright & Co.
Disc Medicine Analyst Ratings
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $79
Morgan Stanley Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
Disc Medicine to Participate in Upcoming Investor Conferences
BMO Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $112
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Raises Target Price to $118
Douglas Tsao's Buy Rating on Disc Medicine Driven by Program Advancements and Strategic Financing
LifeSci Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $85
Disc Medicine's Strong Financial Position and Promising Clinical Developments Drive Buy Rating
Wedbush Raises Disc Medicine Price Target to $83 From $75, Maintains Outperform Rating
Disc Medicine | 10-Q: Q3 2024 Earnings Report
Disc Medicine | 8-K: Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
Disc Medicine's Q3 Net Loss Widens
Disc Medicine Reports Q3 EPS (89c), Consensus ($1.05)
Express News | Disc Medicine: Cash, Cash Equivalents and Marketable Securities Were $487.4 Mln as of September 30, 2024